MyTIME
Melatonin supplementation To reduce the Induction of labour rate in first-time MothErs:
The MyTIME Clinical Trial
MyTIME is a double-blinded, randomised, placebo-controlled clinical trial funded by the Medical Research Future Fund, and led by Professor Zoe Bradfield from Curtin University, Western Australia. The MyTIME trial will evaluate if daily melatonin supplementation from week 39 of pregnancy will reduce induction of labour rates, as melatonin works with oxytocin to support uterine contractions. We will also explore how melatonin affects sleep quality and duration, and blood glucose levels of those with gestational diabetes in pregnancy.
Around 530 women from the Women and Newborn Health Service have taken part in this study from King Edward Memorial Hospital, Osborne Park Hospital, The Family Birth Centre and the Community Midwifery Program.
The Study medication is melatonin 3mg, which is taken orally. Melatonin is known to be safe for pregnant women and babies. We hope the results from this study will provide women with greater opportunity to avoid unnecessary induction of labour in the future.
This study has been approved by the WA Health Central Human Research Ethics Committee (RGS0000006283).
The MyTIME trial is supported by the Medical Research Future Fund (GNTMRFF#2023945) and Curtin University.
ANZ Clinical Trial Registry number: ACTRN12623000502639.